



FINANCIAL TEAR SHEET

Corporate Profile

Apricus is committed to developing sexual health therapies in areas of high unmet needs. We have disciplined leadership focused on execution and are driving near-term shareholder value through regulatory approval, commercialization and partnering initiatives.

Stock Performance

APRI (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$1.62
Change (%)	▲ 0.02 (1.25%)
Volume	158,959
52 Week High	\$4.07
52 Week Low	\$0.86
Market Cap	\$24,344,827
Rolling EPS	-0.93
PE Ratio	0
Shares Outstanding	15,215,517

Data as of 11/20/17 3:59 p.m. ET



Recent Headlines

- 11/02/17
[Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results](#)
- 10/26/17
[Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call](#)
- 10/10/17
[Apricus Biosciences to Present at the 2017 BIO Investor Forum](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
-------------	------

11/02/17	8-K
11/02/17	10-Q
11/02/17	S-3
10/24/17	EFFECT

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)

© Apricus Biosciences, Inc.